In Europe, biosimilar medicines have captured 7% more of the biologics market over a 5-year period

Growing number of biologic therapies offers future opportunities for biosimilar development

White Paper: Anatomy of a failure to launch: A review of barriers to generic and biosimilar market entry and the use of competition law as a remedy

(more…)

Educational material on biosimilar medicines, developed by IGBA (International Generic and Biosimilar Medicines Association)

(more…)

(more…)

Policy Roadmap for Medicines Manufacturing Leadership

Call for tenders SANTE/2020/C3/29 for the supply of medicinal products used for intensive care patients subject to the novel coronavirus (COVID-19) disease – policy and technical concerns

COVID-19 “Round 2” – Findings & way forward (Kearney)

Preparing for a potential second COVID-19 wave. Joint statement by Medicines for Europe and EFPIA with Kearney

LESSONS LEARNED FROM COVID-19 – POLICY PAPER

Physicians recognised potential of Value Added Medicines

Medicines For Europe